Abstracts tagged "adhesion molecules and rheumatoid arthritis (RA)"

Abstract Number: 2659 • 2013 ACR/ARHP Annual Meeting
Antibodies To Citrullinated Enolase, Fibrinogen, and Vimentin Are Associated With Markers Of Endothelial Dysfunction In First-Degree Relatives Of Patients With Rheumatoid Arthritis: The Studies Of The Etiology Of Rheumatoid Arthritis
Jan M. Hughes-Austin¹, Kendra A. Young², Kevin D. Deane³, Michael H. Weisman⁴, Jane H. Buckner⁵, Ted R. Mikuls⁶, James R. O'Dell⁷, Richard M. Keating⁸, Peter K. Gregersen⁹, Jeremy Sokolove¹⁰, William H. Robinson¹¹, V. Michael Holers¹² and Jill M. Norris², ¹Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Med Ctr, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁷Dept of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology Section, The University of Chicago, Chicago, IL, ⁹Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁰VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ¹¹Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹²Rheumatology Division, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Among rheumatoid arthritis (RA) patients, antibodies to citrullinated protein antigens (ACPA) have been detected in atherosclerotic plaques. In particular, antibodies to citrullinated fibrinogen (cit-fib)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].